Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of the "Urinary Tract Infections Drugs Price Analysis and Strategies - 2016" report to their offering.
Urinary Tract Infections Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Urinary Tract Infections market.
The research answers the following questions:
- What are the key drugs marketed for Urinary Tract Infections and their clinical attributes? How are they positioned in the Global Urinary Tract Infections market?
- What are the unit prices and annual treatment cost for Urinary Tract Infections therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Urinary Tract Infections drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Urinary Tract Infections?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Urinary Tract Infections including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Urinary Tract Infections
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Urinary Tract Infections market
- Urinary Tract Infections Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Urinary Tract Infections New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/ps47ps/urinary_tract
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Urological Disorders Drugs


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Anta Sports Expands Global Footprint With Strategic Puma Stake
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Samsung Electronics Shares Jump on HBM4 Mass Production Report
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



